tiprankstipranks
Patrys Limited Reports Delay in PAT-DX1 Trials
Company Announcements

Patrys Limited Reports Delay in PAT-DX1 Trials

Patrys Limited (AU:PAB) has released an update.

Pick the best stocks and maximize your portfolio:

Patrys Limited has announced a delay in the clinical development of its cancer treatment drug PAT-DX1 due to ongoing specification testing, which is now expected to conclude by the end of July 2024. This testing is crucial for releasing the drug for clinical trials, and the delay affects the commencement of clinical activities. The company is focused on developing therapies for various cancers using its deoxymab platform and has committed to updating stakeholders on any further developments.

For further insights into AU:PAB stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskPatrys Limited Strengthened by R&D Tax Incentive
TipRanks Australian Auto-Generated NewsdeskPatrys Limited AGM Resolutions Successfully Passed
TipRanks Australian Auto-Generated NewsdeskPatrys Limited Shifts Focus to Promising PAT-DX3 Development
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App